Astegolimab ELISA Kit

Catalog No.

KDF88301

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human IL1RL1 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Astegolimab in the sample competitively binds to the pre-coated protein with biotin-labeled Astegolimab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Astegolimab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Astegolimab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

46.88 - 3,000 ng/mL

Sensitivity

32.28 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	1369.3	369.0	86.7	1284.7	370.8	80.0
Standard deviation	110.5	20.4	8.8	110.9	21.9	11.0
CV (%)	8.1	5.5	10.2	8.6	5.9	13.7

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

AMG-282, MSTT-1041A, RG-6149, RO-7187807, CAS: 2173054-79-8

Background

Astegolimab, a human IgG2mAb, selectively inhibits the IL-33 receptor, ST2. Approved biologic therapies for severe asthma mainly benefit patients with elevated blood eosinophils (type 2-high), but limited options are available for patients with low blood eosinophils (type 2-low).

Advancements in Biologic Therapies for Pediatric Asthma: Emerging Therapies and Future Directions., PMID:40486460

Biologic Therapies for Severe Asthma: Current Insights and Future Directions., PMID:40364184

Targeting alarmins in asthma: From bench to clinic., PMID:39855362

Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials., PMID:39589286

Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins., PMID:38762432

Mechanistic role of RND3-regulated IL33/ST2 signaling on cardiomyocyte senescence., PMID:38724005

Factors contributing to the nonlinear pharmacokinetics of astegolimab: a close examination of potential causes., PMID:37791725

Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial., PMID:36519984

IL-33 antagonism does not improve chronic atopic dermatitis: What can we learn?, PMID:36270492

Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis., PMID:36041655

Investigational approaches for unmet need in severe asthma., PMID:35786146

Specific Therapy for T2 Asthma., PMID:35455709

Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial., PMID:35339234

Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma., PMID:34964491

Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires., PMID:34346168

Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial., PMID:33872652

Document Download

Astegolimab ELISA Kit.pdf